English  |  正體中文  |  简体中文  |  Total items :2826152  
Visitors :  31805493    Online Users :  983
Project Commissioned by the Ministry of Education
Project Executed by National Taiwan University Library
 		 
Scope Adv. Search
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
About TAIR
About TAIR

Browse By
Institution
Author
Title
Date
Statistics Chart
Institution Facts
Trend

News
2019臺灣學術機構典藏
研討會
機構典藏系統RC7版本已
發佈

Copyright
Publisher & Journal Policy
TAIR Copyright Conference Minutes

Related Links
機構典藏計畫網站
ROAR
OpenDOAR
SHERPA
OAIster
JAIRO
Ira
DSPACE
RWWR
臺大學術典藏NTU Scholars
Taiwan Academic Institutional Repository >  Browse by Author

"miller v a"

Return to Browse by Author
Sorting by Title Sort by Date

Showing items 1-8 of 8  (1 Page(s) Totally)
1 
View [10|25|50] records per page

Institution Date Title Author
臺大學術典藏 2022-06-27T07:02:08Z Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase 2 trial Yang J.C.H.; Shih J.-Y.; Su W.-C.; Hsia T.-C.; Tsai C.-M.; Ou S.H.I.; CHONG-JEN YU; Chang G.-C.; Ho C.-L.; Sequist L.V.; Dudek A.Z.; Shahidi M.; Cong X.J.; Lorence R.M.; Yang P.-C.; Miller V.A.
臺大學術典藏 2020-12-02T02:34:00Z Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase 2 trial Yang J.C.H.; Shih J.-Y.; Su W.-C.; Hsia T.-C.; Tsai C.-M.; Ou S.H.I.; Yu C.-J.; Chang G.-C.; Ho C.-L.; Sequist L.V.; Dudek A.Z.; Shahidi M.; Cong X.J.; Lorence R.M.; PAN-CHYR YANG; Miller V.A.
臺大學術典藏 2020-08-13T06:33:49Z Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase 2 trial Miller V.A.; Yang P.-C.; Lorence R.M.; Cong X.J.; Shahidi M.; Dudek A.Z.; Sequist L.V.; Yang J.C.H.; JIN-YUAN SHIH; Su W.-C.; Hsia T.-C.; Tsai C.-M.; Ou S.H.I.; Yu C.-J.; Chang G.-C.; Ho C.-L.
臺大學術典藏 2020-05-26T09:27:07Z Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase 2 trial Miller V.A.;Yang P.-C;Lorence R.M;Cong X.J;Shahidi M;Dudek A.Z;Sequist L.V;Ho C.-L;Chang G.-C;Yu C.-J;Ou S.H.I;Tsai C.-M;Hsia T.-C;Su W.-C;Shih J.-Y;Chih-Hsin Yang; CHIH-HSIN YANG; Shih J.-Y; Su W.-C; Hsia T.-C; Tsai C.-M; Ou S.H.I; Yu C.-J; Chang G.-C; Ho C.-L; Sequist L.V; Dudek A.Z; Shahidi M; Cong X.J; Lorence R.M; Yang P.-C; Miller V.A.
臺大學術典藏 2020-05-26T09:27:07Z Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): A phase 2b/3 randomised trial Chih-Hsin Yang;Lorence R.M;Cong X.J;Shahidi M;Chao T.-Y;Tan E.-H;Crino L;Heo D.S;Sun Y;Wang M;Su W.-C;Zhou C;Kim S.-W;Park K;Chen Y.-M;Cadranel J;Hirsh V;Miller V.A; Miller V.A; Hirsh V; Cadranel J; Chen Y.-M; Park K; Kim S.-W; Zhou C; Su W.-C; Wang M; Sun Y; Heo D.S; Crino L; Tan E.-H; Chao T.-Y; Shahidi M; Cong X.J; Lorence R.M; CHIH-HSIN YANG
臺大學術典藏 2020-05-26T09:27:06Z Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1 Chmielecki J; Lin Y.-L; Pan Y; Wang L; De Stanchina E; Shien K; Aoe K; Toyooka S; Kiura K; Fernandez-Cuesta L; Fidias P; CHIH-HSIN YANG; Miller V.A; Riely G.J; Kris M.G; Engelman J.A; Vnencak-Jones C.L; Dias-Santagata D; Ladanyi M; Pao W.; Pao W.;Ladanyi M;Dias-Santagata D;Vnencak-Jones C.L;Engelman J.A;Kris M.G;Riely G.J;Miller V.A;Chih-Hsin Yang;Fidias P;Fernandez-Cuesta L;Kiura K;Toyooka S;Aoe K;Shien K;De Stanchina E;Wang L;Pan Y;Lin Y.-L;Chmielecki J;Moran T;Arcila M.E;Sequist L.V;Ohashi K; Ohashi K; Sequist L.V; Moran T; Arcila M.E
臺大學術典藏 2018-09-10T08:44:19Z International association for the study of lung cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma Brambilla, E.; Noguchi, M.; Nicholson, A.G.; Geisinger, K.R.; Yatabe, Y.; Beer, D.G.; Powell, C.A.; Riely, G.J.; Van Schil, P.E.; Garg, K.; Austin, J.H.M.; Asamura, H.; Rusch, V.W.; Hirsch, F.R.; Scagliotti, G.; Mitsudomi, T.; Huber, R.M.; Ishikawa, Y.; Jett, J.; Sanchez-Cespedes, M.; Sculier, J.-P.; Takahashi, T.; Tsuboi, M.; Vansteenkiste, J.; Wistuba, I.; Yang, P.-C.; Aberle, D.; Brambilla, C.; Flieder, D.; Franklin, W.; Gazdar, A.; Gould, M.; Hasleton, P.; Henderson, D.; Johnson, B.; Johnson, D.; Kerr, K.; Kuriyama, K.; Lee, J.S.; Miller, V.A.; Petersen, I.; Roggli, V.; Rosell, R.; Saijo, N.; Thunnissen, E.; Tsao, M.; Yankelewitz, D.; Travis, W.D.; PAN-CHYR YANGet al.
臺大學術典藏 2013 Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: Results of a randomized phase iib/iii trial (lux-lung 1) Hirsh V;Cadranel J;Cong X.J;Fairclough D;Finnern H.W;Lorence R.M;Miller V.A;Palmer M;Chih-Hsin Yang; Hirsh V; Cadranel J; Cong X.J; Fairclough D; Finnern H.W; Lorence R.M; Miller V.A; Palmer M; CHIH-HSIN YANG

Showing items 1-8 of 8  (1 Page(s) Totally)
1 
View [10|25|50] records per page

DSpace Software Copyright © 2002-2004  MIT   &  Hewlett-Packard   /   Enhanced by   NTU Library IR team